Aryl Hydrocarbon Receptor Activation by Benzo[

Animals Basic Helix-Loop-Helix Transcription Factors / metabolism Benzo(a)pyrene / pharmacology Disease Models, Animal Mice Receptors, Aryl Hydrocarbon / metabolism Salmonella Infections, Animal / pathology Salmonella enterica Sepsis Shock, Septic
IL-10 IL-22 Salmonella infection aryl hydrocarbon receptor (AhR) benzo[a]pyrene (BaP) immunomodulation interferon-γ interleukin (IL)-12 septic shock systemic inflammatory response syndrome (SIRS)

Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
20 02 2022
Historique:
received: 01 12 2021
revised: 11 02 2022
accepted: 13 02 2022
entrez: 25 2 2022
pubmed: 26 2 2022
medline: 9 4 2022
Statut: epublish

Résumé

This study focused on immunomodulatory effects of aryl hydrocarbon receptor (AhR) activation through benzo[

Identifiants

DOI: 10.3390/cells11040737 PMID: 35203386 PMC: PMC8870598
pubmed: 35203386
pii: cells11040737
doi: 10.3390/cells11040737
pmc: PMC8870598
pii:
doi:

Substances chimiques

Ahr protein, mouse 0
Basic Helix-Loop-Helix Transcription Factors 0
Receptors, Aryl Hydrocarbon 0
Benzo(a)pyrene 3417WMA06D

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Federal Institute for Risk Assessment
ID : FK 3-1329-432
Organisme : Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V.
ID : Internal project funding and CIMD_CED-AhR

Références

J Toxicol Environ Health A. 2007 Aug;70(15-16):1391-4
pubmed: 17654259
Toxicol Sci. 2011 Mar;120 Suppl 1:S49-75
pubmed: 21059794
Met Ions Life Sci. 2011;8:157-85
pubmed: 21473381
Immunol Rev. 2011 Mar;240(1):196-210
pubmed: 21349095
Nat Immunol. 2010 Sep;11(9):854-61
pubmed: 20676095
J Immunol. 2005 Mar 15;174(6):3484-92
pubmed: 15749884
Biochemistry. 1998 Aug 18;37(33):11508-15
pubmed: 9708986
J Immunol. 1995 Dec 1;155(11):5397-401
pubmed: 7594556
J Immunol. 2001 Nov 1;167(9):5304-15
pubmed: 11673546
Cell Metab. 2020 Apr 7;31(4):837-851.e10
pubmed: 32213346
Annu Rev Pharmacol Toxicol. 2000;40:519-61
pubmed: 10836146
Mol Cell Biol. 2009 Dec;29(24):6391-400
pubmed: 19822660
Trends Immunol. 2009 Sep;30(9):447-54
pubmed: 19699679
Toxicology. 2018 Nov 1;409:80-90
pubmed: 30053493
J Immunol. 2007 Jul 1;179(1):247-55
pubmed: 17579044
Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8185-9
pubmed: 1325649
Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6731-6
pubmed: 8692887
Front Immunol. 2020 Jan 21;10:3155
pubmed: 32038650
Toxicol Sci. 2011 Feb;119(2):293-307
pubmed: 21097750
Science. 1994 Jul 1;265(5168):106-9
pubmed: 8016643
Br J Cancer. 1962 Sep;16:507-17
pubmed: 14014727
Clin Immunol Immunopathol. 1992 Jan;62(1 Pt 2):S11-7
pubmed: 1370262
Science. 1995 May 5;268(5211):722-6
pubmed: 7732381
J Immunol. 1994 Jul 1;153(1):165-72
pubmed: 8207233
J Proteome Res. 2015 Jan 2;14(1):164-82
pubmed: 25362887
Infect Immun. 2006 Oct;74(10):5679-86
pubmed: 16988243
N Engl J Med. 1970 Sep 24;283(13):686-91
pubmed: 4916913
Annu Rev Pharmacol Toxicol. 2003;43:309-34
pubmed: 12540743
Anal Biochem. 1982 Oct;126(1):131-8
pubmed: 7181105
Trends Pharmacol Sci. 2020 Dec;41(12):900-908
pubmed: 33097284
J Immunol. 2007 May 15;178(10):6200-7
pubmed: 17475847
J Biol Chem. 1998 Aug 28;273(35):22708-13
pubmed: 9712901
Nature. 2014 Aug 28;512(7515):387-92
pubmed: 25119038
Toxicol Appl Pharmacol. 2010 Jul;246(1-2):18-28
pubmed: 20350561
Annu Rev Immunol. 2014;32:403-32
pubmed: 24655296
Int Immunol. 2014 Apr;26(4):209-20
pubmed: 24343818
Cancer Res. 1986 Jun;46(6):2735-9
pubmed: 3516385
Infect Immun. 2020 Sep 18;88(10):
pubmed: 32601109
J Environ Pathol Toxicol. 1980 Jun-Jul;3(5-6):537-67
pubmed: 7441099
Vaccine. 2006 May 29;24(22):4779-93
pubmed: 16647169
Biol Chem. 2006 Sep;387(9):1219-26
pubmed: 16972790
Immunol Cell Biol. 2013 Oct;91(9):568-75
pubmed: 23999131
DNA Cell Biol. 1998 Sep;17(9):811-22
pubmed: 9778040
Berl Munch Tierarztl Wochenschr. 1996 Oct;109(10):369-74
pubmed: 8999767
Berl Munch Tierarztl Wochenschr. 1996 Sep;109(9):325-9
pubmed: 9054331
Front Immunol. 2018 Sep 19;9:2033
pubmed: 30283437
Br J Surg. 1994 Sep;81(9):1306-8
pubmed: 7953393
Toxicol Ind Health. 1991 May;7(3):141-57
pubmed: 1949056
J Clin Immunol. 1992 Jul;12(4):239-47
pubmed: 1512298
Int Immunopharmacol. 2012 Aug;13(4):490-8
pubmed: 22634480
Shock. 2002 Jun;17(6):463-7
pubmed: 12069181
Mol Endocrinol. 2007 Dec;21(12):2941-55
pubmed: 17823304
Chem Biol. 1995 Dec;2(12):841-5
pubmed: 8807817
J Exp Med. 2009 Aug 31;206(9):2027-35
pubmed: 19703987
Immunity. 2003 Jan;18(1):155-67
pubmed: 12530984
Toxicol Appl Pharmacol. 2004 Nov 15;201(1):40-52
pubmed: 15519607
J Immunol. 2007 Nov 15;179(10):6952-62
pubmed: 17982086
Chem Biol Interact. 2021 Jan 5;333:109330
pubmed: 33245929
Nutr Cancer. 2008;60(2):216-21
pubmed: 18444153
Toxicol Sci. 2011 Dec;124(2):327-38
pubmed: 21948866
FEBS Lett. 2005 Mar 28;579(9):1904-10
pubmed: 15792794
Nature. 1964 May 23;202:781-4
pubmed: 14187619
Nature. 2014 Jul 10;511(7508):184-90
pubmed: 24930766
Toxicol Lett. 2018 Oct 15;296:106-113
pubmed: 30099064
J Immunol. 2008 Dec 1;181(11):7891-901
pubmed: 19017979
Proc Natl Acad Sci U S A. 2021 Mar 23;118(12):
pubmed: 33723080

Auteurs

Christiane Fueldner (C)

Department of Preclinical Development and Validation, Fraunhofer Institute for Cell Therapy and Immunology, 04103 Leipzig, Germany.

Sina Riemschneider (S)

Department of Preclinical Development and Validation, Fraunhofer Institute for Cell Therapy and Immunology, 04103 Leipzig, Germany.

Janine Haupt (J)

Department of Preclinical Development and Validation, Fraunhofer Institute for Cell Therapy and Immunology, 04103 Leipzig, Germany.
Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD, 04103 Leipzig, Germany.

Harald Jungnickel (H)

Department of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR), 10589 Berlin, Germany.

Felix Schulze (F)

Department of Preclinical Development and Validation, Fraunhofer Institute for Cell Therapy and Immunology, 04103 Leipzig, Germany.

Katharina Zoldan (K)

Department of Preclinical Development and Validation, Fraunhofer Institute for Cell Therapy and Immunology, 04103 Leipzig, Germany.

Charlotte Esser (C)

Leibniz Research Institute for Environmental Medicine, 40225 Düsseldorf, Germany.

Sunna Hauschildt (S)

Faculty of Life Sciences, University of Leipzig, 04103 Leipzig, Germany.

Jens Knauer (J)

Department of Preclinical Development and Validation, Fraunhofer Institute for Cell Therapy and Immunology, 04103 Leipzig, Germany.

Andreas Luch (A)

Department of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR), 10589 Berlin, Germany.

Stefan Kalkhof (S)

Department of Preclinical Development and Validation, Fraunhofer Institute for Cell Therapy and Immunology, 04103 Leipzig, Germany.
Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD, 04103 Leipzig, Germany.
Institute for Bioanalysis, Department of Applied Sciences, Coburg University of Applied Sciences, 96450 Coburg, Germany.

Jörg Lehmann (J)

Department of Preclinical Development and Validation, Fraunhofer Institute for Cell Therapy and Immunology, 04103 Leipzig, Germany.
Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD, 04103 Leipzig, Germany.
ORCID: 0000-0001-8560-648X

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Aryl Hydrocarbon Receptor Activation by Benzo[
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteurs de transcription à motif basique hélice-boucle-hélice › Aryl Hydrocarbon Receptor Activation by Benzo[
questionsmedicales.fr › Composés polycycliques › Hydrocarbures aromatiques polycycliques › Pyrènes › Benzopyrènes › Benzo[a]pyrène › Aryl Hydrocarbon Receptor Activation by Benzo[
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Aryl Hydrocarbon Receptor Activation by Benzo[
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Aryl Hydrocarbon Receptor Activation by Benzo[
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Récepteurs à hydrocarbure aromatique › Aryl Hydrocarbon Receptor Activation by Benzo[
questionsmedicales.fr › Maladies de l'animal › Salmonelloses animales › Aryl Hydrocarbon Receptor Activation by Benzo[
questionsmedicales.fr › Bactéries › Proteobacteria › Gammaproteobacteria › Enterobacteriaceae › Salmonella › Salmonella enterica › Aryl Hydrocarbon Receptor Activation by Benzo[
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › Sepsie › Aryl Hydrocarbon Receptor Activation by Benzo[
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Choc › Syndrome de réponse inflammatoire généralisée › Choc septique › Aryl Hydrocarbon Receptor Activation by Benzo[